NCT06844669 2026-03-03
HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy
Washington University School of Medicine
Phase 2 Active not recruiting
Clinical Trials
80 trialsNCT06332131 2026-02-09
Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature
Abramson Cancer Center at Penn Medicine
Enrolling by invitation
NCT06443645 2026-02-04
SCARA-B
Centre Paul Strauss
Recruiting
NCT04044872 2026-02-02
Hyperpolarized Carbon 13-Based Metabolic Imaging to Detect Radiation-Induced Cardiotoxicity
University of Texas Southwestern Medical Center
Phase EARLY_PHASE1 Terminated
NCT06595147 2026-01-08
BE-FITTER
University of Alberta
Phase NA Recruiting
NCT06023576 2026-01-02
A Study of Blood Pressure Control During Cancer Treatment
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07299812 2025-12-23
BRAVE-HEART
Fondazione IRCCS Policlinico San Matteo di Pavia
Recruiting
NCT07254221 2025-12-10
ROSUBREAST
Shiraz University of Medical Sciences
Phase 4 Not yet recruiting
NCT03787966 2025-11-19
ATOPE
Universidad de Granada
Phase NA Completed
NCT05559164 2025-11-14
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
Rutgers, The State University of New Jersey
Phase 2 Recruiting
NCT05078190 2025-11-06
CCT2
Abramson Cancer Center at Penn Medicine
Active not recruiting
NCT03418961 2025-10-08
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
SWOG Cancer Research Network
Phase 3 Recruiting
NCT07191730 2025-09-25
ML-CardioTox
University Hospital, Caen
Not yet recruiting
NCT06155331 2025-08-19
Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients
Tanta University
Phase 2 Completed
NCT03862131 2025-07-29
PROACT
Washington University School of Medicine
Phase 2 Terminated
NCT02772367 2025-07-16
Generation of Heart Muscle Cells From Blood or Skin Cells of Breast Cancer Patients
Memorial Sloan Kettering Cancer Center
Recruiting
NCT04737265 2025-07-03
NTproBNP-Guide
Abramson Cancer Center at Penn Medicine
Phase 1/2 Completed
NCT05786014 2025-06-12
The Effects of Two Exercise Interventions on Breast Cancer Patients Undergoing Cardiotoxic Chemotherapies
University of Virginia
Phase NA Completed
NCT06310330 2025-06-06
TRUST-ACE
Norwegian University of Science and Technology
Phase NA Recruiting
NCT06930521 2025-04-16
JUSTIFY
Women's College Hospital
Phase NA Not yet recruiting
NCT04568161 2025-04-03
Effect of Anthracyclines and Cyclophosphamide on Cardiovascular Responses
University of Sao Paulo General Hospital
Phase NA Completed
NCT03711110 2025-03-21
CARTIER
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Phase NA Recruiting
NCT06881940 2025-03-18
CARPTOX-BC
Instituto Nacional de Cardiologia Ignacio Chavez
Phase NA Not yet recruiting
NCT05465031 2025-03-14
Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
Silesian Centre for Heart Diseases
Phase 4 Recruiting
NCT05403736 2025-02-06
CARMA
Cedars-Sinai Medical Center
Phase NA Completed
NCT06622954 2024-10-02
PROTECT-COR
Erasmus Medical Center
Phase NA Recruiting
NCT06595316 2024-09-19
Exercise for Ameliorating Chemotherapy Cardiotoxicity
University of Hull
Phase NA Not yet recruiting
NCT03748550 2024-08-21
EXACT2
Nova Scotia Health Authority
Phase NA Active not recruiting
NCT05851053 2024-05-29
BLOC-II
University Medical Center Groningen
Recruiting
NCT05467111 2024-04-11
CardioProtEx
Technical University of Madrid
Phase NA Recruiting
NCT04896242 2024-04-04
Multimodal Assesment of Acute Cardiac Toxicity Induced by Thoracic Radiotherapy in Cancer Patients
Pontificia Universidad Catolica de Chile
Completed
NCT06341842 2024-04-02
PROTECT
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase 2 Recruiting
NCT06282796 2024-02-28
Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy
First Hospital of China Medical University
Recruiting
NCT02605512 2023-11-08
BACCARAT
Institut de Radioprotection et de Surete Nucleaire
Phase NA Completed
NCT02881203 2023-07-27
BRAVEHeart
University of Sydney
Phase NA Completed
NCT05921279 2023-07-25
UCARE
National University of Ireland, Galway, Ireland
Recruiting
NCT05960214 2023-07-25
AQUA
Istanbul University
Completed
NCT05927246 2023-07-03
RADAF
Istanbul University
Completed
NCT05892146 2023-06-07
Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction
National Cheng-Kung University Hospital
Phase NA Unknown
NCT01719562 2023-05-19
MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy With Exercise Capacity Addendum
Wake Forest University Health Sciences
Phase NA Completed
NCT05732051 2023-03-17
NARNIA
University Hospital, Akershus
Phase 2 Recruiting
NCT03850171 2023-02-27
Cancer Adverse Effects PReventIon With Care & Exercise: the CAPRICE Study
Insel Gruppe AG, University Hospital Bern
Phase NA Terminated
NCT05728632 2023-02-23
CONTROL
Humanitas Hospital, Italy
Phase 3 Unknown
NCT05733026 2023-02-17
Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Doxorubicin Among Egyptian Breast Cancer Patients
Ain Shams University
Unknown
NCT05454553 2022-11-29
EDIPE
Institut de cancérologie Strasbourg Europe
Phase NA Unknown
NCT00436566 2022-08-05
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
Mayo Clinic
Phase 2 Completed
NCT03940625 2022-05-25
ANKE
Heinrich-Heine University, Duesseldorf
Phase NA Completed
NCT05146843 2022-04-08
The Impact of Chronic Mitochondrial Antioxidant Supplementation on CardiovascularToxicity in Breast Cancer Patients
D'Or Institute for Research and Education
Phase NA Unknown
NCT05298072 2022-03-28
Identification of Novel Inflammation-related Biomarkers for Early Detection of Anthracycline-induced Cardiotoxicity in Breast Cancer Patients
University Hospital, Essen
Unknown
NCT02236806 2022-02-01
SAFE
Azienda Ospedaliero-Universitaria Careggi
Phase 3 Unknown